Bio-Rad Labs (BIO) to Acquire Stilla Technologies
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/18/2026
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Baidu slips as Q2 results miss estimates despite growth in AI cloud business
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
- Home Depot beats estimates, reaffirms fiscal 2026 guidance
- Citi says positioning risk is shifting from short squeezes to profit-taking
- Wall Street indexes slip as oil prices rise, retail results awaited
- Micron rises as White House presses Apple to avoid Chinese memory chips
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- Tech selloff pulls Wall Street to two-week lows as bond yields climb
- Francisco Partners to acquire Weave Communications for $650M
Bio-Rad Offers to Acquire Digital PCR Developer Stilla Technologies
February 13, 2025 4:15 PM ESTTransaction To Complement Bio-Rads Existing Digital PCR Portfolio and Accelerate Development of Next-Generation Digital PCR Solutions
HERCULES, Calif.--(BUSINESS WIRE)-- Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company has entered into a binding offer to purchase all equity interests in Stilla Technologies (Stilla). The acquisition remains subject to consultation with relevant employee representatives, regulatory approvals, and other customary closing conditions, and is expected to close by the end of the third quarter of 2025.
With... More
